Q2 2025 EPS Estimates for United Therapeutics Co. Raised by Zacks Research (NASDAQ:UTHR)

United Therapeutics Co. (NASDAQ:UTHR) – Investment analysts at Zacks Research lifted their Q2 2025 earnings per share (EPS) estimates for shares of United Therapeutics in a report issued on Wednesday, July 24th. Zacks Research analyst K. Shah now expects that the biotechnology company will earn $5.69 per share for the quarter, up from their prior forecast of $5.59. The consensus estimate for United Therapeutics’ current full-year earnings is $24.87 per share. Zacks Research also issued estimates for United Therapeutics’ Q3 2025 earnings at $5.48 EPS, Q4 2025 earnings at $5.02 EPS, FY2025 earnings at $21.98 EPS, Q1 2026 earnings at $5.56 EPS, Q2 2026 earnings at $5.54 EPS and FY2026 earnings at $21.68 EPS.

Several other brokerages have also weighed in on UTHR. Wells Fargo & Company upped their target price on United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 12th. Morgan Stanley cut shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their target price for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. The Goldman Sachs Group increased their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. HC Wainwright raised their price target on shares of United Therapeutics from $300.00 to $400.00 and gave the company a “buy” rating in a report on Thursday. Finally, JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a report on Tuesday, May 21st. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $330.64.

United Therapeutics Trading Up 1.4 %

NASDAQ UTHR opened at $336.37 on Friday. The company has a market capitalization of $14.92 billion, a PE ratio of 15.90, a price-to-earnings-growth ratio of 1.45 and a beta of 0.55. United Therapeutics has a 1-year low of $208.62 and a 1-year high of $343.98. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. The firm’s fifty day simple moving average is $301.73 and its 200-day simple moving average is $256.49.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The company had revenue of $677.70 million during the quarter, compared to the consensus estimate of $620.31 million. During the same quarter in the prior year, the firm earned $4.86 EPS. The company’s revenue was up 33.7% compared to the same quarter last year.

Insider Activity

In related news, Director Christopher Causey sold 2,240 shares of the business’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $259.91, for a total transaction of $582,198.40. Following the completion of the transaction, the director now owns 4,185 shares of the company’s stock, valued at approximately $1,087,723.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other United Therapeutics news, Director Christopher Patusky sold 1,310 shares of the firm’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $264.35, for a total value of $346,298.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Christopher Causey sold 2,240 shares of the company’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $259.91, for a total transaction of $582,198.40. Following the transaction, the director now directly owns 4,185 shares of the company’s stock, valued at approximately $1,087,723.35. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 100,884 shares of company stock valued at $29,622,803. 12.50% of the stock is owned by insiders.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently added to or reduced their stakes in UTHR. Norges Bank bought a new stake in shares of United Therapeutics in the 4th quarter worth approximately $100,519,000. Swedbank AB bought a new position in United Therapeutics in the first quarter worth $97,316,000. Nordea Investment Management AB boosted its stake in United Therapeutics by 677.6% during the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after buying an additional 262,222 shares in the last quarter. Avidity Partners Management LP bought a new stake in United Therapeutics in the 4th quarter valued at $52,158,000. Finally, Canada Pension Plan Investment Board raised its stake in shares of United Therapeutics by 567.2% in the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock valued at $41,533,000 after buying an additional 153,700 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.